biotech.today

Details

  • ●Modalities: antibodies, CRISPR enzymes, therapeutic proteins
  • ●Therapeutic areas: Undisclosed
  • ●Key targets:
  • ●Indications: Undisclosed
  • ●Funding: $35M

Key considerations

  • ●AI tools in use: ProGen2, OpenCRISPR, Profluent Platform
  • ●$35M Series A (2023)
  • ●OpenCRISPR-1 announcement 2024
  • ●IgDesign publication 2024 showing in vitro antibody validation
Get live updates on Profluent Bio’s hiring, filings, and partnerships. Follow in BT Pro →
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)

Key people

Ali Madani

Founder & CEO

protein-language-modelsgenerative-proteins
Visit website →LinkedIn →